Trastornos de ansiedad

Biliografía

1.Wittchen HU, Jacobi F, Rehm J, et al.: The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 9: 655–79 CrossRef MEDLINE

2.WHO: Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO (http:/ / apps.who.int/ iris/ bitstream/handle/ 10665/ 254610/ WHO-MSD-MER-2017.2-eng.pdf;jsessionid=829EAD6A4E0473EBDE28F4FD23B8D556?sequence=1) (last accessed on 22 August 2018).

3.Dilling H: Internationale Klassifikation Psychischer Störungen: ICD-10 Kapitel V (F); Klinisch-diagnostische Leitlinien. 8th revised edition ICD-10-GM 2011. Bern: Huber 2011.

4.WHO: ICD-11. https:/ / icd.who.int/ dev11/ l-m/ en. (last accessed on 22 August 2018).

5.Silove D, Alonso J, Bromet E, et al.: Pediatric-onset and adult-onset separation anxiety disorder across countries in the world mental health survey. Am J Psychiatry 2015; 172: 647–56 CrossRef MEDLINEPubMed Central

6.Baldwin DS, Gordon R, Abelli M, Pini S: The separation of adult separation anxiety disorder. CNS Spectrums 2016; 21: 289–94 CrossRef MEDLINE

7.Rogoll J, Petzold M, Ströhle A: Selektiver Mutismus. Nervenarzt 2018; 89: 591–602 CrossRef MEDLINE

8.Kossowsky J, Pfaltz MC, Schneider S, Taeymans J, Locher C, Gaab J: The separation anxiety hypothesis of panic disorder revisited: a meta-analysis. Am J Psychiatry 2013; 170: 768–81 CrossRef MEDLINE

9.Grant BF, Goldstein RB, Saha TD, et al.: Epidemiology of DSM-5 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions III. JAMA Psychiatry 2015; 72: 757–66 CrossRef MEDLINE PubMed Central

10.Meier SM, Petersen L, Mattheisen M, Mors O, Mortensen PB, Laursen TM: Secondary depression in severe anxiety disorders: a population-based cohort study in Denmark. Lancet Psychiatry 2015; 2: 515–23 CrossRef

11.Tawakol A, Ishai A, Takx RA, et al.: Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study. Lancet 2017; 389: 834–45 CrossRef

12.Batty GD, Russ TC, Stamatakis E, Kivimäki M: Psychological distress in relation to site specific cancer mortality: pooling of unpublished data from 16 prospective cohort studies. BMJ 2017; 356: j108.

13.Gottschalk MG, Domschke K: Novel developments in genetic and epigenetic mechanisms of anxiety. Curr Opin Psychiatry 2016; 29: 32–8 CrossRef MEDLINE

14.Klauke B, Deckert J, Reif A, Pauli P, Domschke K: Life events in panic disorder—an update on „candidate stressors“. Depress Anxiety 2010; 27: 716–30 CrossRef

15.Schiele MA, Domschke K: Epigenetics at the crossroads between genes, environment and resilience in anxiety disorders. Genes Brain Behav 2018; 17: e12423 CrossRef MEDLINE

16.Ziegler C, Richter J, Mahr M, et al.: MAOA gene hypomethylation in panic disorder—reversibility of an epigenetic risk pattern by psychotherapy. Transl Psychiatry 2016; 6: e773 CrossRef MEDLINE PubMed Central

17.Bandelow B, Baldwin D, Abelli M, et al.: Biological markers for anxiety disorders, OCD and PTSD—a consensus statement. Part I: neuroimaging and genetics. World J Biol Psychiatry 2016; 17: 321–65 CrossRef MEDLINE

18.Bandelow B, Baldwin D, Abelli M, et al.: Biological markers for anxiety disorders, OCD and PTSD: a consensus statement. Part II: neurochemistry, neurophysiology and neurocognition. World J Biol Psychiatry 2017; 18: 162–214 CrossRef MEDLINE PubMed Central

19.Lebow MA, Chen A: Overshadowed by the amygdala: the bed nucleus of the stria terminalis emerges as key to psychiatric disorders. Mol Psychiatry 2016; 4: 450–63 CrossRef MEDLINE PubMed Central

20.Bandelow B, Wiltink J, Alpers GW, et al.: Deutsche S3-Leitlinie Behandlung von Angststörungen. www.awmf.org/ uploads/ tx_szleitlinien/ 051–028l_S3_ Angstst%C3%B6rungen_2014–05_2.pdf (last accessed on 13 August 2018).

21.Leichsenring F, Salzer S, Beutel ME, et al.: Psychodynamic therapy and cognitive-behavioral therapy in social anxiety disorder: a multicenter randomized controlled trial. Am J PSychiatry 2013; 170: 759–67 CrossRef MEDLINE

22.Gloster AT, Wittchen HU, Einsle F, et al.: Psychological treatment for panic disorder with agoraphobia: a randomized controlled trial to examine the role of therapist-guided exposure in situ in CBT. J Consult Clin Psychol 2011; 79: 406–20 CrossRef CrossRef MEDLINE

23.Diemer J, Mühlberger A, Pauli P, Zwanzger P: Virtual reality exposure in anxiety disorders: impact on psychophysiological reactivity. World J Biol Psychiatry 2014; 15: 427–42 CrossRef MEDLINE

24.Bandelow B, Reitt M, Röver C, Michaelis S, Görlich Y, Wedekind D: Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol 2015; 30: 183–92 CrossRef MEDLINE

25.Bandelow B, Sagebiel A, Belz M, Görlich Y, Michaelis S, Wedekind D: Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies. Br J Psychiatry 2018; 212: 333–8 CrossRef MEDLINE

26.Bonnet U, Scherbaum N: How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol 2017; 27: 1185–215 CrossRef MEDLINE

27.Perna G, Alciati A, Riva A, Micieli W, Caldirola D: Long-term pharmacological treatments of anxiety disorders: an updated systematic review. Curr Psychiatry Rep 2016; 18: 23 CrossRef MEDLINE

28.Soyka M: Treatment of benzodiazepine dependence. N Engl J Med 2017; 376: 1147–57 CrossRefMEDLINE

29.Normann N, Emmerik AAP, Morina N: The efficacy of metacognitive therapy for anxiety and depression: a meta-analytic review. Depression Anxiety 2014; 31: 402–11 CrossRef MEDLINE

30.Gloster AT, Sonntag R, Hoyer J, et al.: Treating treatment-resistant patients with panic disorder and agoraphobia using psychotherapy: a randomized controlled switching trial. PPS 2015; 84: 100–9 CrossRef